# Clinical Trials Data EGFR - Document 67

# Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

## Clinical Trial: https://clinicaltrials.gov/study/NCT02140333

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Histological diagnosis of NSCLC with phase IIIB or IV disease;\n2. Sensitive mutation EGFR gene (18, 19 del, 21 L858R gene mutation) (mutation detection methods:ARMS-PCR, sequence method)\n3. Never received anti-tumor therapies for the advanced stage;\n4. Never used EGFR inhibitors;\n5. Measurable disease by RECIST criteria;\n6. Male or female patients \\>=18 years of age;\n7. ECOG karnofsky performance 0\\~3, life expectancy is greater than 12 weeks;\n8. Patients must be accessible for treatment and follow-up;\n\nExclusion Criteria:\n\n1. Previously used EGFR inhibitors\n2. Mix ingredients in patients with squamous cell carcinoma, small cell lung cancer;\n3. Allergic to erlotinib;\n4. Non-measurable lesions\n5. Pregnant or lactating women;\n6. Patients having other factors that preventing researchers from enrollment them.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the clinical trial eligibility criteria provided, a patient with an EGFR gene mutation would be eligible for the trial if they meet the following specific conditions related to the gene mutation:  
  
1. The patient must have a sensitive EGFR gene mutation, specifically 18, 19 deletions, or the 21 L858R gene mutation. These mutations should be detected using ARMS-PCR or sequence methods.  
  
As long as the patient also meets the other inclusion criteria and does not meet any of the exclusion criteria, they would be eligible for the trial.   
  
Thus, if your patient has one of the specified sensitive EGFR mutations and meets the additional criteria (such as being in the correct stage of NSCLC, no prior treatments for advanced disease, and so on), they would be considered eligible for this clinical trial according to the given criteria.